Comparison of ctDNA profiles from HR+/HER2-low and HR+/HER2-0 advanced breast cancer patients

被引：0
|
作者：
Dobric, N. [1 ]
Dandachi, N. [1 ]
Klocker, E. V. [1 ]
Suppan, C. [1 ]
Graf, R. [2 ]
Hasenleithner, S. [2 ]
Jost, P. J. [1 ]
Heitzer, E. [2 ]
Balic, M. [1 ]
机构：
[1] Med Univ Graz, Div Oncol, Dept Internal Med, Graz, Austria
[2] Med Univ Graz, Inst Human Genet, Graz, Austria
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.667
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
491P
引用
收藏
页码：S387 / S387
页数：1
相关论文
共 50 条
  • [11] Current trends in the treatment of HR+/HER2+breast cancer
    Kay, Charlene
    Martinez-Perez, Carlos
    Meehan, James
    Gray, Mark
    Webber, Victoria
    Dixon, J. Michael
    Turnbull, Arran K.
    FUTURE ONCOLOGY, 2021, 17 (13) : 1665 - 1681
  • [12] Comprehensive genomic characterization of HER2-low and HER2-0 breast cancer
    Paolo Tarantino
    Hersh Gupta
    Melissa E. Hughes
    Janet Files
    Sarah Strauss
    Gregory Kirkner
    Anne-Marie Feeney
    Yvonne Li
    Ana C. Garrido-Castro
    Romualdo Barroso-Sousa
    Brittany L. Bychkovsky
    Simona DiLascio
    Lynette Sholl
    Laura MacConaill
    Neal Lindeman
    Bruce E. Johnson
    Matthew Meyerson
    Rinath Jeselsohn
    Xintao Qiu
    Rong Li
    Henry Long
    Eric P. Winer
    Deborah Dillon
    Giuseppe Curigliano
    Andrew D. Cherniack
    Sara M. Tolaney
    Nancy U. Lin
    Nature Communications, 14
  • [13] MONARCH 3: Abemaciclib as initial therapy for patients with HR+/HER2-advanced breast cancer
    Di Leo, A.
    Toi, M.
    Campone, M.
    Sohn, J.
    Paluch-Shimon, S.
    Huober, J.
    Park, I. H.
    Tredan, O.
    Chen, S-C.
    Manso, L.
    Freedman, O.
    Jaliffe, G. G.
    Forrester, T.
    Frenzel, M.
    Barriga, S.
    Smith, I. C.
    Bourayou, N.
    Goetz, M. P.
    ANNALS OF ONCOLOGY, 2017, 28
  • [14] The efficacy and safety of tinengotinib in patients with advanced or metastatic HR+/HER2-breast cancer or TNBC
    Sarina, Piha-Paul
    Xu, Binghe
    Fan, Ying
    Yuan, Yuan
    Lavasani, Sayeh
    Mortimer, Joanne
    Goel, Sanjay
    Tsimberidou, Apostolia
    Ibrahim, Nuhad
    Abouharb, Sausan
    Barcenas, Carlos
    Lheme, Adaeze
    Karp, Daniel
    Ahnert, Jordi Rodon
    Dumbrava, Ecaterina
    Fan, Jean
    Peng, Peng
    Sun, Caixia
    Wang, Hui
    Hennessy, Katie
    Fu, Ximei
    Xu, Ruolan
    Ni, Shumao
    Wu, Frank
    Meric-Bernstam, Funda
    CANCER RESEARCH, 2024, 84 (09)
  • [15] MONARCH 3: Abemaciclib as Initial Therapy for Patients with HR+/HER2-Advanced Breast Cancer
    Leo, A. D.
    Toi, M.
    Campone, M.
    Sohn, J. H.
    Shimon, S. P.
    Huober, J.
    Park, I. H.
    Tredan, O.
    Chen, S. -C.
    Manso, L.
    Freedman, O.
    Jaliffe, G. G.
    Forrester, T. D.
    Frenzel, M.
    Barriga, S.
    Smith, I. C.
    Bourayou, N.
    Goetz, M. P.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 5 - 5
  • [16] Comprehensive genomic characterization of HER2-low and HER2-0 breast cancer
    Tarantino, P.
    Gupta, H.
    Hughes, M. E.
    Files, J.
    Strauss, S.
    Kirkner, G.
    Feeney, A. -M.
    Li, Y.
    Garrido-Castro, A. C.
    Barroso-Sousa, R.
    Bychkovsky, B. L.
    Dilascio, S.
    Sholl, L.
    Macconaill, L.
    Lindeman, N.
    Johnson, B. E.
    Meyerson, M.
    Jeselsohn, R.
    Qiu, X.
    Li, R.
    Long, H.
    Winer, E. P.
    Dillon, D.
    Curigliano, G.
    Cherniack, A. D.
    Tolaney, S. M.
    Lin, N. U.
    NATURE COMMUNICATIONS, 2023, 14 (01)
  • [17] Everolimus and Exemestane An Innovative Therapeutic Option for Patients with advanced HR+, HER2-Breast Cancer
    Grischke, Eva-Maria
    Geberth, Matthias
    Harbeck, Nadia
    AKTUELLE NEUROLOGIE, 2014, 41 (08) : 4 - 6
  • [18] Clinical outcome for HR+/HER2-stage IV breast cancer patients
    Goto, Risa
    Aruga, Tomoyuki
    Honda, Yahoi
    Idera, Nami
    Horiguchi, Kazumi
    Miyamoto, Hiromi
    Yamashita, Toshinari
    Horiguchi, Shinnichiro
    Kuroi, Katsumasa
    ANNALS OF ONCOLOGY, 2015, 26 : 142 - 142
  • [19] Efficacy of chemotherapy in patients with HR+/HER2-Invasive lobular breast cancer
    Yaghi, Marita
    Bilani, Nadeem
    Dominguez, Barbara
    Zerdan, Maroun Bou
    Li, Hong
    Saravia, Diana
    Stone, Elizabeth
    Nahleh, Zeina
    CANCER TREATMENT AND RESEARCH COMMUNICATIONS, 2023, 34
  • [20] Prognostic Parameters of Palbociclib in HR+/HER2-Advanced Breast Cancer: A Narrative Review
    Wang, Wei
    Wu, Jiayi
    Chen, Keyu
    Wang, Xiaojia
    Shao, Xiying
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2023, 22
12345